Hepatitis C
📧 Sign up to get email alerts when something new happens for Hepatitis C.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2017-07-24Clinical Trial Update: Effects of Direct Antiviral Agents on Hepatitis C Virus Arthropathy
An update on a clinical trial investigating the effects of direct-acting antiviral agents on hepatitis C virus arthropathy. The status of th…
-
CLINICAL_TRIALS trial_result · 2017-07-21Clinical Trial Update: Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults [Phase 1]
Phase 1 study to assess how omeprazole and ritonavir influence the pharmacokinetics of GSK2336805 in healthy adults; the study was completed…
-
CLINICAL_TRIALS trial_result · 2017-07-21Clinical Trial Update: Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805 [Phase 1]
This update notes the completion of a Phase 1 cross-over trial evaluating the cardiovascular effects of the hepatitis C investigational drug…
-
FDA approval · 2017-07-18FDA Approved: VOSEVI — Original Application (Gilead Sciences, Inc.)
VOSEVI (sofosbuvir/velpatasvir/voxilaprevir) is approved as an oral, fixed-dose combination for treatment of chronic hepatitis C virus infec…
-
CLINICAL_TRIALS trial_result · 2017-07-14Clinical Trial Update: SR-BI and Antiviral Treatment Response in HCV
A clinical trial update examining the relationship between the SR-BI receptor and antiviral treatment response in chronic hepatitis C, spons…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2017-07-12Clinical Trial Update: Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C [Phase 3]
A Phase 3 trial evaluating adding Vitamin D to standard of care for untreated Chronic Hepatitis C in Egyptian patients was withdrawn.
-
CLINICAL_TRIALS trial_result · 2017-07-12Clinical Trial Update: Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia [Phase 4]
Phase 4 trial update on community-based treatment of chronic hepatitis C monoinfection and HIV coinfection in DC; study completed with resul…
-
CLINICAL_TRIALS trial_result · 2017-07-11Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis [Phase 3]
Phase 3 trial evaluating the safety and efficacy of ombitasvir/paritaprevir/ritonavir with dasabuvir and ribavirin in adults with genotype 1…
-
CLINICAL_TRIALS trial_result · 2017-07-11Clinical Trial Update: Study of Long-term Peg Intron vs. Colchicine in Non-responders. [Phase 4]
Phase 4 clinical trial comparing long-term PegIntron (pegylated interferon alfa-2b) versus Colchicine in hepatitis C patients with advanced …
-
CLINICAL_TRIALS research · 2017-07-11Clinical Trial Update: Impact of Insulin Resistance on Therapeutic Response for Oral Treatment of Chronic Hepatitis C Virus Infection
This clinical trial update examines whether insulin resistance influences the therapeutic response to oral treatment for chronic hepatitis C…
-
CLINICAL_TRIALS trial_result · 2017-07-07Clinical Trial Update: A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients [Phase 3]
Phase 3 trial evaluating TMC435 in combination with PegIFN alfa-2a and ribavirin for treatment-naïve or treatment-experienced chronic hepati…
-
CLINICAL_TRIALS trial_result · 2017-07-07Clinical Trial Update: A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects [Phase 1]
A first-in-human Phase 1 study of GSK2485852 in chronically infected Hepatitis C patients has been terminated. The study assessed safety, to…
-
CLINICAL_TRIALS trial_result · 2017-07-02Clinical Trial Update: An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals [Phase 1]
Open-label, non-randomized Phase 1 dose-escalation trial evaluating safety and tolerability of Alb-Interferon Alfa 2b given every two weeks …
-
CLINICAL_TRIALS research · 2017-07-02Clinical Trial Update: Association Between Hepatitis C Virus Infection and Hematologic and Thyroid Cancers
This study investigates whether Hepatitis C virus infection is associated with an increased risk of hematologic malignancies and thyroid can…
-
CLINICAL_TRIALS trial_result · 2017-07-02Clinical Trial Update: Transplant-Related Accelerated Progression of Hepatitis C
A completed clinical trial examining transplant-related accelerated progression of hepatitis C in patients with cirrhosis.
-
CLINICAL_TRIALS trial_result · 2017-07-02Clinical Trial Update: Long-Term Therapy With Ribavirin for Chronic Hepatitis C [Phase 4]
Phase 4 clinical trial update noting the completion of long-term ribavirin therapy for chronic hepatitis C.
-
CLINICAL_TRIALS trial_result · 2017-07-02Clinical Trial Update: Genetics of Hepatitis C Virus Infection
A clinical trial update summarizes genetics research related to Hepatitis C virus infection. The study status is completed.
-
CLINICAL_TRIALS trial_result · 2017-06-29Clinical Trial Update: Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection [Phase 2]
Phase 2 pilot trial assessing the efficacy and safety of the fixed-dose combination sofosbuvir/ledipasvir in treatment-experienced patients …
-
CLINICAL_TRIALS trial_result · 2017-06-29Clinical Trial Update: Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir [Phase 2]
Phase 2 trial evaluating the efficacy and safety of adding Sofosbuvir and Ribavirin to Grazoprevir/Elbasvir in patients with hepatitis C gen…
-
CLINICAL_TRIALS trial_result · 2017-06-28Clinical Trial Update: A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients. [Phase 1]
First-in-human Phase 1 trial of GSK2336805 in healthy volunteers and single-dose administration in chronically infected Hepatitis C patients…
-
CLINICAL_TRIALS trial_result · 2017-06-27Clinical Trial Update: Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection
This clinical trial update summarizes post-approval surveillance data on the use of sofosbuvir plus ribavirin in Japanese patients with chro…
-
EMA approval · 2017-06-23Two new medicines recommended for the treatment of chronic hepatitis C
EMA recommended two new medicines for the treatment of chronic hepatitis C, indicating potential upcoming approvals for improved regimens.
-
CLINICAL_TRIALS trial_result · 2017-06-23Clinical Trial Update: Direct-acting Antivirals and Hepatocellular Carcinoma Recurrence
A completed clinical trial updates the investigation of whether direct-acting antivirals for hepatitis C influence hepatocellular carcinoma …
-
CLINICAL_TRIALS trial_result · 2017-06-15Clinical Trial Update: The Relationship Between MDSCs and NK Cells Activity of CHC Patient Treated by DAAs [EARLY_Phase 1]
Early-phase 1 trial in patients with chronic hepatitis C examined changes in myeloid-derived suppressor cells and natural killer cell activi…
-
CLINICAL_TRIALS trial_result · 2017-06-14Clinical Trial Update: Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects [Phase 1]
Phase 1 pharmacokinetics and safety study of GSK2336805 in subjects with hepatic impairment and matched healthy controls has completed.